| Literature DB >> 31861112 |
Tiziana Corsello1, Andrzej S Kudlicki2,3, Roberto P Garofalo1,2,4,5, Antonella Casola1,2,4.
Abstract
Exposure to environmental tobacco smoke (ETS) is a known risk factor for the development of chronic lung diseases, cancer, and the exacerbation of viral infections. Extracellular vesicles (EVs) have been identified as novel mediators of cell-cell communication through the release of biological content. Few studies have investigated the composition/function of EVs derived from human airway epithelial cells (AECs) exposed to cigarette smoke condensate (CSC), as surrogates for ETS. Using novel high-throughput technologies, we identified a diverse range of small noncoding RNAs (sncRNAs), including microRNA (miRNAs), Piwi-interacting RNA (piRNAs), and transfer RNA (tRNAs) in EVs from control and CSC-treated SAE cells. CSC treatment resulted in significant changes in the EV content of miRNAs. A total of 289 miRNAs were identified, with five being significantly upregulated and three downregulated in CSC EVs. A total of 62 piRNAs were also detected in our EV preparations, with five significantly downregulated and two upregulated in CSC EVs. We used TargetScan and Gene Ontology (GO) analysis to predict the biological targets of hsa-miR-3913-5p, the most represented miRNA in CSC EVs. Understanding fingerprint molecules in EVs will increase our knowledge of the relationship between ETS exposure and lung disease, and might identify potential molecular targets for future treatments.Entities:
Keywords: airway epithelial cells; miRNAs; microvesicles; next generation sequencing; secondhand smoke
Mesh:
Substances:
Year: 2019 PMID: 31861112 PMCID: PMC6953119 DOI: 10.3390/cells8121652
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1Diagram of EV isolation and characterization. EVs were isolated as described and characterized for size by ZetaView® analysis and specific markers by Western blot analysis.
Figure 2Characterization of EVs released from SAE cells under standard (control) or CSC treatment. (A) Absolute size determination (left panel) and concentration (right panel) of control and CSC- EVs by ZetaView® PMX-110 analysis. The particles were tracked and sized based on Brownian motion. The absolute count of EVs was determined and expressed as particles/mL. (B) Western blot analysis of equal amounts of purified EVs (25μg) for CD63, Alix and GM130. Graph shows densitometric analysis of Alix in EVs as mean ± SEM. * indicates a statistical difference comparing CSC EVs versus control-EVs (p value < 0.05). EVs size and concentration, and western blot analysis are representative of three and four experiments, respectively.
Percentage of RNA types in EVs from control and CSC-treated SAE cells. Data represent the mean ± SEM of three independent experiments.
| RNA Type | % Control EVs | % CSC EVs | |
|---|---|---|---|
| protein coding | 2.9 ± 1.3 | 3 ± 1.4 | 0.4 |
| processed transcript | 1.5 ± 0.7 | 1.3 ± 0.7 | 0.4 |
| miRNA | 5.0 ± 0.7 | 7.5 ± 0.8 | 0.04 |
| tRNA | 9.1 ± 4.0 | 12.5 ± 6.2 | 0.3 |
| piRNA | 0.4 ± 0.01 | 0.38 ± 0.02 | 0.3 |
| snoRNA | 6.1± 3.0 | 5.3 ± 2.9 | 0.4 |
| rRNA | 8.1 ± 0.3 | 8.4 ± 0.9 | 0.4 |
| miscRNA | 1.4 ± 0.6 | 2.3 ± 1.0 | 0.2 |
| snRNA | 0.8 ± 0.4 | 0.9 ± 0.4 | 0.4 |
| unannotated | 63.6 ± 9.3 | 57 ± 11.3 | 0.3 |
Top five miRNAs upregulated and three miRNAs downregulated in CSC EVs. Data represent the average of three independent experiments.
| miRNAs | Log2 Fold Change | Read Count (Avg) | ||
|---|---|---|---|---|
| CSC EVs | Control EVs | |||
| hsa-miR-3913-5p | 10.28 | 0.0003 | 356.00 | 1.62 |
| hsa-miR-574-5p | 10.25 | 0.0006 | 183.57 | 0 |
| hsa-miR-656-5p | 9.76 | 0.0014 | 126.40 | 0 |
| hsa-miR-3180-5p | 9.21 | 0.0022 | 39.98 | 0 |
| hsa-miR-500a-5p | 8.91 | 0.0033 | 84.5 | 0 |
| hsa-miR-618 | −9.25 | 0.00241 | 0 | 76.053 |
| hsa-miR-222-5p | −8.78 | 0.00472 | 0 | 55.44 |
| hsa-miR-130b-5p | −8.20 | 0.005 | 0 | 38.35 |
Figure 3Validation of miRNAs expression in SAE cells and EVs. RNA extracted from SAE cells control and CSC-treated (left panel) and from control and CSC EVs (right panel) was subjected to miRNAs analysis by RT-PCR. Fold changes in miRNA expression were determined by 2-ΔΔCT method and represent mean ± SEM normalized to small nucleolar RNA C/D box 61 (SNORD61). * and ** indicates a statistical difference comparing CSC EVs versus control-EVs (* p value < 0.05; ** p value < 0.01). Data is representative of four independent experiments.
Top five piRNAs downregulated and two piRNAs upregulated in CSC EVs. Data represent the average of three independent experiments.
| piRNAs | Log2 Fold Change | Read Count (Avg) | ||
|---|---|---|---|---|
| CSC EVs | Control EVs | |||
| piR-36705 | −10.19 | 0.002 | 0 | 191.02 |
| piR-37183 | −10.19 | 0.002 | 0 | 191.02 |
| piR-59260 | −10.19 | 0.002 | 0 | 191.02 |
| piR-36924 | −10.24 | 0.002 | 0.32 | 358.4 |
| piR-52900 | −10.28 | 0.004 | 0 | 211.63 |
| piR-31985 | 10.52 | 0.004 | 498.48 | 0 |
| piR-50603 | 9.78 | 0.001 | 276.51 | 0 |
Figure 4Validation of piRNAs expression in SAE cells and EVs. RNA extracted from control and CSC-treated (left panel) SAE cells and from control and CSC EVs (right panel) was subjected to piRNAs analysis by RT-PCR. Fold changes in piRNA expression were determined by 2-ΔΔCT method and represent mean ± SEM normalized to small nucleolar RNA C/D box 61 (SNORD61). * and ** indicates a statistical difference comparing CSC EVs versus control-EVs (* p value < 0.05; ** p value < 0.01). Data is representative of four independent experiments.
Predicted target genes of hsa-miR-3913-5p.
| Target Gene | Cumulative Weighted | Target Gene | Cumulative Weighted |
|---|---|---|---|
| PLEKHS1 | −1.39 | AC005477.1 | −0.58 |
| GCSAM | −1 | FCGR2A | −0.58 |
| BLNK | −0.75 | ETNK1 | −0.55 |
| ACMSD | −0.74 | MYF5 | −0.55 |
| AP000708.1 | −0.72 | NME4 | −0.54 |
| KCNAB2 | −0.7 | APOA4 | −0.54 |
| IQCK | −0.7 | KRTAP4-6 | −0.53 |
| RHAG | −0.65 | AL049747.1 | −0.53 |
| S100A10 | −0.65 | ZNF740 | −0.53 |
| NHLH1 | −0.61 | SEPT3 | −0.53 |
| OR51F2 | −0.61 | ITGAE | −0.53 |
| VSNL1 | −0.6 | PRKCDBP | −0.52 |
| ERGIC1 | −0.6 | TPMT | −0.52 |
| PYY | −0.59 | C21ORF33 | −0.5 |
| YWHAZ | −0.59 | RP11-321F6.1 | −0.5 |
| PSMC4 | −0.59 |
GO term enrichment functional analysis. Top gene targets categorized in three biologically-relevant categories.
| Term | Genes | Enrichment |
|---|---|---|
|
| ||
| lipid transport | NME4, APOA4 | 19.21 |
| regulation of mRNA stability | YWHAZ, PSMC4 | 14.17 |
| extracellular matrix organization | ITGAE, MYF5 | 7.44 |
| RNA polymerase II promoter | MYF5, NHLH1 | 2.84 |
|
| ||
| cytosol | APOA4, YWHAZ, KCNAB2, PSMC4, VSNL1, ACMSD, ETNK1, TPMT, BLNK | 2.06 |
| membrane | KCNAB2, PSMC4, VSNL1, ETNK1, RHAG, ERGIC1 | 2.07 |
| blood microparticle | APOA4, YWHAZ | 9.99 |
| plasma membrane | KCNAB2, ITGAE, OR51F2, ETNK1, GCSAM, FCGR2A, RHAG, BLNK | 1.47 |
| extracellular exosome | APOA4, YWHAZ, ACMSD, S100A10, FCGR2A, TPMT | 1.62 |
| cytoskeleton | SEPT3, KCNAB2 | 4.09 |
| cell junction | SEPT3, KCNAB2 | 3.3 |
| integral component of membrane | KCNAB2, ACMSD, OR51F2, ETNK1, S100A10, FCGR2A, RHAG, ERGIC1 | 1.17 |
|
| ||
| lipid binding | NME4, APOA4, S100A10 | 13.97 |
| protein binding | YWHAZ, SEPT3, MYF5, ACMSD, GCSAM, S100A10, PRKCDBP, ERGIC1, APOA4, NME4, PSMC4, VSNL1, ETNK1, FCGR2A, PYY, PLEKHS1, BLNK | 1.36 |
| transcriptional activation only | MYF5, NHLH1 | 14.80 |
| hydrolase activity | PSMC4, ACMSD | 7.36 |
| protein kinase binding | YWHAZ, GCSAM | 3.74 |